Updated 2/15/2016
Curriculum Vitae
KAPIL N. BHALLA, M.D., FACP
PERSONAL:
Office Address: MRC 3 East, Rm 3056, 12902 Magnolia Drive, Tampa, FL 33612-9497
Home Address: 2701 Chambray Lane, Tampa, FL 33611
Telephone:
Office: 813-903-6861; Fax: 813-903-6817
E-mail:
bhallakn@moffitt.usf.edu
Citizenship:
Naturalized citizen of the U.S.A.
EDUCATION:
Years
1970
1970-1976
Training
Undergraduate: Inter-Science
Medical School
7/76-6/77
7/77-6/78
7/78-6/80
7/80-6/83
Internship: Pathology
Internship: Internal Medicine
Residency: Internal Medicine
Fellowship:Hematology/Oncology
Location
University of Delhi, India
Maulana Azad Medical College,
University of Delhi, India
St. Michael’s Medical Center, Newark, N.J.
St. Michael’s Medical Center, Newark, N.J.
St. Michael’s Medical Center, Newark, N.J.
Columbia University College of
Physicians & Surgeons, New York, N.Y.
SPECIALTY CERTIFICATION:
1979
1982
1983
Diplomate, American Board of Internal Medicine
Diplomate, American Board of Internal Medicine, Subspecialty of Hematology
Diplomate, American Board of Internal Medicine, Subspecialty of Medical Oncology
MEDICAL LICENSURE:
1977
1980
1989
1995
1999
New Jersey
New York
South Carolina
Georgia
Florida
#33772
#142739
#14364
#040313
#ME 78908
FACULTY APPOINTMENTS:
Years
7/83-12/84
Position
Instructor in Medicine
Location
Division of Medical Oncology and Hematology
Columbia University College of Physicians &
Surgeons; New York, N.Y.
1/85-6/89
Assistant Professor of
Medicine
Division of Medical Oncology and Hematology
Columbia University College of
Physicians & Surgeons; New York, N.Y.
7/89-6/94
Associate Professor of
Medicine
Division of Hematology/Oncology
Department of Medicine
Medical University of South Carolina, Charleston, S.C.
Kapil N. Bhalla, M.D.
Page 2
7/94-7/95
Professor of Medicine
With Tenure
Division of Hematology/Oncology
Department of Medicine
Medical University of South Carolina, Charleston, S.C.
8/95-12/98
Professor of Medicine
With Tenure
Division of Hematology/Oncology
Department of Medicine and Winship Cancer
Emory University School of Medicine, Atlanta, GA
1996-1998
Associate Director,
Translational Sciences
Emory University School of Medicine
Winship Cancer Center, Atlanta, GA
1/99- 5/00
Associate Director,
Sylvester Distinguished
Professor of Oncology,
(Endowed Chair)
Chief, Division of Clinical
and Translational Research
5/00-present
University of Miami, School of Medicine
Sylvester Comprehensive Cancer Center
Clinical and Translational Research, Miami, FL
Professor, Departments of
University of South Florida, Tampa, Florida
Interdisciplinary Oncology,
Biochemistry & Molecular Biology
Pharmacology & Therapeutics,
Internal Medicine
HOSPITAL APPOINTMENTS:
Years
Position
Location
7/83-6/89
Director of Medical Oncology
Outpatient Clinics
Assistant Attending Physician
Columbia-Presbyterian Medical Center
New York, New York
7/89-7/95
Attending Physician
Medical University Hospital Charleston, S.C.
8/95-2000
Attending Physician
Emory Clinic and Emory University Hospital; Atlanta, GA
5/00-Present
Attending Physician
Scientific Director,
Comprehensive Breast Cancer
Program
Moffitt Cancer Center & Research Institute, Tampa, FL
12/00-Present
Principal Investigator
Moffitt Cancer Center & Research Institute, Tampa, FL
Breast Cancer SPORE application
AWARDS AND HONORS:
1969
7/83—6/85
7/85—6/88
2/88—1/93
7/92—6/97
1993-1994
National Science Talent Search Scholarship, India
Leukemia Society of America Fellow Award
American Cancer Society Clinical Oncology Career Development Award
FIRST Award, The National Cancer Institute
Leukemia Society of America Scholar Award
Health Science Foundation Developing Scholar Award of the Medical
University of South Carolina, Charleston, SC
Kapil N. Bhalla, M.D.
Page 3
MEMBERSHIP IN PROFESSIONAL/SCIENTIFIC SOCIETIES:
American Society of Clinical Oncology, Member
American Society of Hematology, Member
American Federation of Clinical Research, Member
American College of Physicians, Fellow
American Association for Cancer Research, Member
International Society of Experimental Hematology, Member
American Society for the Advancement of Science, Member
EDITORIAL ACTIVITIES:
Associate Editor: Cancer Research
Member Editorial Board: Blood (1994-2000)
Member Editorial Board: Leukemia
Member Editorial Board: Clinical Cancer Research
Member Editorial Board: Cancer Biology and Therapy
Member Editorial Board: Cell Cycle
REFEREE FOR SCIENTIFIC MANUSCRIPTS:
Journal of Clinical Investigation
Experimental Hematology
Biochemical Pharmacology
Journal of Biologic Chemistry
Oncogene
Cancer Research
Cancer Chemotherapy Pharmacology
Journal of Clinical Oncology
Molecular Pharmacology
GRANT REVIEW ACTIVITIES:
Member of the Apoptosis Special Emphasis Panel, National Institutes of Health, 1999.
Member of the Experimental Therapeutics-2 Study Section, National Cancer Institute, National Institutes of
Health, 1993-1997.
Member of the Clinical Research, Cancer Control and Epidemiology Committee, American Cancer Society,
1997.
Member of the Pathobiology I Panel, Department of Defense USAMRMC Breast Cancer Research Program,
1997.
Member of the Scientific Review Group, National Cancer Institute, Special Emphasis Panel for Program
Project Review, October 2000
Member of the Scientific Review Group, National Cancer Institute, SPORE in Skin, Prostate and Breast
Cancers, Grant Review Committee, 2001
Member of the Leukemia & Lymphoma Society, Translational Grant Review Subcommittee, 2001 - 2005
Member of the Scientific Review Group, National Cancer Institute, Special Emphasis Panel for Program
Project Review, October 2001
Kapil N. Bhalla, M.D.
Page 4
CURRENT GRANT/AWARD SUPPORT AND FUNDING:
1.
National Cancer Institute: R01 CA63382 “Taxane-Induced Apoptosis: Regulation in Breast Cancer Cells."
9/1/98 - 4/30/03; K. Bhalla (PI, 20% effort); ADC: $122,779 TDC: $736,674.
2.
National Cancer Institute: RO1 CA090717-01 "Arsenic-Based Therapy of Bcr-Abl Positive Leukemias"
6/15/01-5/31/04, K. Bhalla (PI, 20% effort); ADC: $207,500 TDC: $622,500
3.
National Cancer Institute: RO1 CA95188-01 “Gleevec Plus Novel Anti-Bcr-Abl Strategies in Leukemias.”
04/01/02 - 03/30/06, K. Bhalla (PI, 20% effort); ADC $222,500 TDC $890,000
4.
National Cancer Institute: R01 CA56613-08 “Control of Ara-C-Induced Apoptosis of AML Cells.”
04/01/02 - 03/30/05; K. Bhalla (PI, 20% effort); ADC: $178,000 TDC: $534,000
5.
Novartis Corporation: “A Study of Molecular Mechanisms of Anti-Leukemic Activity and Circumvention
of Resistance to Gleevec (STI-571) In Bcr-Abl Positive Leukemias” K. Bhalla PI TDC $50,000
6.
Aventis Corporation: “In vitro and in vivo studies of the molecular mechanisms of anti-breast cancer activity
of Flavopiridol alone or in combination with Docetaxel, K. Bhalla TDC $60,000
GRANT AWARD SUPPORT PENDING:
1.
National Cancer Institute: R21 CA94530-01 “Antitumor Activity of Epothilone B in Ovarian Cancer.”
07/01/02 - 06/30/04, K. Bhalla (PI, 15% effort); ADC $250,000 TDC $500,000
2.
National Cancer Institute: 1 P50 CA098157-01 “SPORE in Breast Cancer” 12/01/02 - 11/30/07, K. Bhalla (PI,
30% effort); ADC $1,786,630
3.
National Cancer Institute: Ro1 CA099999-01 “Targeting Apoptosis Signaling in Breast Cancer Cells” 04/01/03
– 03/31/08, K. Bhalla (PI, 20% effort); ADC $250,000 TDC $1,250,000
CLINICAL RESEARCH ACTIVITIES:
A.
B.
NIH/CTEP Sponsored Studies
1.
A Phase II Study of Arsenic Trioxide for Induction Therapy of Adult Patients with Relapsed or
Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Previously
Untreated Chronic Myeloid Leukemia with Blast Crisis (NSC #706363, NCI protocol # 1230)
2.
A Phase II study of epothilone B analogue BMS 247550 in relapse and/or refractory stage III or IV
ovarian epithelial cancer, following front-line treatment with platinum plus taxane-based
chemotherapy. (NCI Protocol # 3632)
3.
A Phase I Study of Epothilone B Analog (BMS 247550) in Combination with Carboplatin in
Recurrent and/or Refractory Solid Tumors (Co-PI) (NCI Protocol # 5306)
CALGB (Cancer and Leukemia Group B) Studies
Study Co-Chair:
1.
CALGB 8944: Intensive Doxorubicin surgery, CMF, and Radiation Therapy for Stage III
Breast Cancer-A study of efficacy with Pharmacokinetics and antigenic monitoring. A
Phase II Study.
Kapil N. Bhalla, M.D.
2.
C.
Page 5
CALGB 9021: High dose cytarabine with or without concurrent GM-CSF in the remission
induction of relapsed or refractory acute myelogenous leukemia and untreated blast crisis of
CML. A Phase II Study.
Industry Sponsored Trials:
Study Co-Chair:
1.
A Phase I Clinical and Pharmacologic Study of CI-1033 plus weekly Taxotere and
Carboplatin for all tumor types with special emphasis on lunch cancers, mesotheliomas and
breast cancers. (Co-PI)
2.
A Phase I/II Study of Arsenic Trioxide (Trisenox) in Combination with Imatinib Mesylate
(Gleevec) in Chronic Myelogenous Leukemia in Blast Crisis and Ph+ Acute Lymphoblastic
Leukemia. (Co-PI)
3.
A Phase II randomized open-label study of letrozole in combination with two dose levels of
oral CCI-779, or letrozole alone, in postmenopausal women with locally advanced or
metastatic breast cancer (Co-PI)
EDUCATIONAL ACTIVITIES:
1993-1997:
Adjunct Faculty member of School of Graduate Studies, Medical University of South Carolina.
1997-1999:
Adjunct Faculty member, Graduate Division, Biochemistry & Molecular Biology Program: Emory
University.
1999-2000:
Professor, Microbiology & Immunology Graduate Program: University of Miami.
2000-present:
Professor, Biochemistry & Molecular Biology Graduate Program: University of South Florida
2000-present:
Professor, Pharmacology & Therapeutics Graduate Program: University of South Florida
2000-present:
Professor, Department of Interdisciplinary Oncology: University of South Florida
2001-present:
Professor, Internal Medicine: University of South Florida
2001-present:
Co-Director, Department of Interdisciplinary Oncology Grand Rounds, Moffitt Cancer Center and
University of South Florida
MENTOR:
Graduate Students Thesis Committee Chair:
Medical University of South Carolina
Ana Maria Ibrado, M.D., Ph.D.
Gloria Bullock, M.D., Ph.D.
Vidyashankar Ponnathpur, M.S.
Emory University
Charles Perkins, Ph.D.
University of South Florida
Michael Lee, Ph.D.
PUBLICATIONS:
1.
Grant S, Bhalla K, Sheffield K, Schainholz D, Weinstein IB, Fischer P: Differential toxicity of bacterial cloned
interferon (IFLrR) toward leukemic vs. normal human bone marrow cells. Biochem Biophys Res Comm 108 (3):
1048-1055, 1982.
2.
Grant S, Bhalla K, Rauscher F III, Cadman E: Potentiation of Ara-C metabolism and cytoxicity by IMPY (2,3didhydro-1H-imidazole- [1,2b]pyrazole) in the human promyelocytic leukemic cells, HL-60. Cancer Res 43:
5093-5100, 1983.
Kapil N. Bhalla, M.D.
Page 6
3.
Bhalla K, Nayak R, Deitch A, Grant S: Synergistic interaction between acivicin (AT-125) and 6-thioguanine in
the murine leukemic L1210: Biochemical and cytokinetic considerations. Biochem Pharmacol 33: 247-254,
1984.
4.
Bhalla K, Nayak R, Grant S: Isolation and characterization of a deoxycytidine kinase deficient, human
promyelocytic leukemia cell line highly resistant to 1--D-arabinofuranosylcytosine. Cancer Res 44: 5029-5037,
1984.
5.
Grant S, Bhalla K, Gleyzer M: Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to
inhibitors of de novo pyrimidine synthesis. Cancer Res 44: 5505-5510, 1984.
6.
Bhalla K, Hindenburg A, Taub RN, Grant S: Isolation and characterization of an anthracycline resistant human
promyelocytic leukemia cell line. Cancer Res 43: 3657-3662. 1985.
7.
Grant S, Bhalla K, Weinstein IB, Pestka S, Mileno MD, Fischer PB: Recombinant human interferon sensitizes
resistant myeloid leukemic cells to induction of terminal differentiation. Biochem Biophys Res Comm 130: 379388, 1985.
8.
Bhalla K, Cole J, MacLaughlin W, Baker M, Arlin Z, Graham G, Grant S: Deoxycytidine stimulates the in
vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and
prostaglandin E1. Blood 68: 1136-1141, 1986.
9.
Grant S, Bhalla K, Gleyzer M: Interaction of deoxycytidine and deoxycytidine analogues in normal and
leukemic myeloid progenitor cells. Leukemia Res 10: 1139-1146, 1986.
10.
Bhalla K, MacLaughlin W, Cole J, Baker M, Arlin Z, Graham G, Grant S: Deoxycytidine preferentially protects
normal versus leukemic myeloid progenitor cells from Ara-C mediated cytotoxicity. Blood 70: 568-571, 1987.
11.
Bhalla K, Cole J, MacLaughlin W, Arlin Z, Baker M, Graham G, Grant S: Effect of Deoxycytidine on the
Metabolism and Cytotoxicity of 5-aza-2’ deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic
human myeloid progenitor cells. Leukemia 1: 814-819, 1987..
12.
Bhalla K, Grant S: Effect of deoxycytidine on the in vitro response of human leukemic cells to inhibitors of de
novo pyrimidine biosynthesis. Cancer Chemother Pharmacol 19: 226-232,1987.
13.
Bhalla K, Birkhofer M, Cole J, MacLaughlin W, Graham G, Grant S, Baker M: Phase I clinical and
pharmacologic study of deoxycytidine. Leukemia 2: 709-710, 1988.
14.
Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G: Effect of rGM-CSF on the metabolism of
cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 2: 810-813, 1988.
15.
Bhalla K, Birkhofer M, Grant S, Graham G: The effect of recombinant human granulocyte macrophage colony
stimulating factor (rGM-CSF) on 3'azido-3'-deoxythymidine (AZT) mediated biochemical and cytotoxic effects
on normal human myeloid progenitor cells. Exp Hematol 17: 17-20, 1989.
16.
Lutzky J, Astor M, Taub RN, Baker MA, Bhalla K, Gervasoni JE, Rosado M, Stewart V, Krishna S,
Hindenburg A: Role of glutathione and dependent enzymes in anthracycline resistant HL-60/AR cells. Cancer
Res 49: 4120-4125, 1989.
17.
Hindenburg A, Gervasoni JE, Krishna S, Stewart VJ, Rosado M, Lutzky J, Bhalla K, Baker MA, Taub RN:
Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline sensitive and resistant HL-60
cells. Cancer Res 49: 4607-4614, 1989.
Kapil N. Bhalla, M.D.
Page 7
18.
Bhalla K, Birkhofer M, Gongrong L, Grant S, MacLaughlin W, Cole J, Graham G, Volsky DJ: 2'Deoxycytidine protects normal human bone marrow progenitor cells in vitro aganist the cytotoxicity of 3'-Azido3'-deoxythymidine (AZT) with preservation of antiretroviral activity. Blood 74: 1923-1928, 1989.
19.
Grant S, Bhalla K, Arlin Z, Howe C: The effect of a prolonged in vitro exposure to 1-B-DArabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU)
human myeloid progenitor cells in suspension culture. Exp. Hematol 18: 41-48, 1990.
20.
Bhalla K, Gongrong L, Cole J, Grant S, MacLaughlin W, Volsky DI: Effect of 2'-deoxycytidine on the in vitro
cytotoxicity of 2', 3'-dideoxycytidine. AIDS 4: 427-431, 1990.
21.
Grant S, Bhalla K: Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'deoxycytidine and 1-B-D-arabinofuranosylcytosine in human leukemia cells. Leukemia Res 15: 205-213, 1991.
22.
Gervasoni JE, Taub RN, Rosado M, Krishna S, Stewart VJ, Knowles DM, Bhalla K,
Ross D, Baker MA, Lutzky J, Hindenburg A: Membrane glycoprotein changes associated with anthracycline
resistance in HL-60 cells. Cancer Chemother Pharmacol 28: 93-101, 1991.
23.
Bhalla K, Birkhofer M, Arlin Z, Grant S, Safah H, Graham G: Differential effect of Interleukin-3 on the
metabolism of high dose cytosine arabinoside in normal versus leukemic bone marrow cells. Exp Hematol 19:
669-673, 1991.
24.
Bhalla K, Birkhofer M, Cole J, Bhalla M, Lutzky J, Hindenburg A, Ince C: Phase I study of a combination of
allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastro-intestinal
and breast cancer. Amer J Clin Oncol 14 (6): 509-513, 1991.
25.
Bhalla K, Swerdlow P, Grant S: Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1B-D arabinofuranosylcytosine in highly resistant human leukemia cells. Blood 78: 2937-2944, 1991.
26.
Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M: Treatment with IL-3 plus GM-CSF improves
the selectivity of Ara-C in vitro against AML blasts. Blood 78: 2674-2679, 1991.
27.
Bhalla K, Holladay C, Lutzky J, Howell S, Ibrado AM, Bullock G, Jasiok M, Singh S: Deoxycytidine protects
normal bone marrow progenitors against Ara-C and Gemcitabine cytotoxicity without compromising their
activity against cisplatin resistant human ovarian cancer cells. Gynecol Oncol 45: 32-39, 1992.
28.
Grant S, Traylor R, Bhalla K, McCrady C, Pettit GR: Effect of combined exposure to Ara-C, Bryostatin-1
and rGM-CSF on in vitro clonogenic growth of normal and leukemic hemopoietic progenitor cells.
Leukemia 6: 432-439, 1992.
29.
Bhalla K, Ross R, Jeter E, Madyastha P, Stuart RK: Granulocyte colony stimulating factor improves
granulocytopenia in Felty’s Syndrome without flare up of arthritis. Amer J Hematol 42: 230-231, 1993.
30.
Bhalla K, Bullock G, Lutzky J, Holladay C, Ibrado AM, Jasiok M, Singh S: Effect of combined treatment
with interleukin-3 and interleukin-6 on 4-Hydroperoxycyclophosphamide mediated reduction in glutathione
levels and cytotoxicity in normal and leukemic bone marrow progenitor cells. Leukemia 6: 814-819, 1992.
31.
Bhalla K, Ibrado AM, Bullock G, Tang CQ, Tourkina E, Huang Y: GM-CSF/IL-3 fusion protein (PIXY
321) enhances high dose Ara-C induced programmed cell death or apoptosis in human myeloid leukemic
cells. Blood 80: 2883-2890, 1992.
32.
Bhalla K, Tourkina E, Huang Y, Tang C, Mahoney ME, Ibrado AM: Effect of hemopoietic growth factors
G-CSF and pIXY 321 on the activity of high dose Ara-C in human myeloid leukemia cells. Leukemia and
Lymphoma 10(Suppl): 123-131, 1993.
Kapil N. Bhalla, M.D.
Page 8
33.
Bhalla K, Ibrado AM, Tourkina E, Tang CQ, Mahoney ME, Huang Y: Taxol induces internucleosomal
DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7:
563-568, 1993.
34.
Kumar GN, Walle K, Bhalla K, Walle T: Binding of taxol to human plasma, albumin and 1-acid
glycoprotein. Res Commun Chemo Pathol Pharmacol 80: 337-344, 1993.
35.
Grant S, Baker M, Bhalla K: Phase I study of a continous infusion of high-dose Ara-C in conjunction with
a fixed dose of 2'deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
Leukemia 7: 1933-1938, 1993.
36.
Bullock G, Tang CQ, Tourkina E, Ibrado AM, Lutzky J, Huang Y, Mahoney ME, Bhalla K: Effect of
combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide induced
programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol 21: 1640-1647, 1993.
37.
Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME:
High dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.
Blood 82: 3133-3140, 1993.
38.
Bhalla K, Ray S, Huang Y, Tang C, Self S, Mahoney ME, Ponnathpur V, Ibrado AM, Bullock G,
Willingham MC: Characterization of a human myeloid leukemia cell line highly resistant to taxol.
Leukemia 8: 465-475, 1994.
39.
Brandt JE, Bhalla K, Hoffman R: Effects of Interleukin-3 and c-kit ligand on the survival of human
hematopoietic progenitor cells and hematopoietic stem cells. Blood 83: 1507-1514, 1994.
40.
Willingham MC, Bhalla K: Transient mitotic phase localization of bcl-2 oncoprotein in human carcinoma
cells and its possible role in prevention of apoptosis. J Histochem and Cytochem 42: 441-450, 1994.
41.
Fan W, Everett ET, Tang C, Cooper T, Fang Q, Bhalla K, Norris JS: Glucocorticoid-mediated inhibition of
taxol-induced apoptosis in leiomyosarcoma cells. Cell Pharmacol 1: 205: 212, 1994.
42.
Tang C, Huang Y, Ponnathpur VS, Ray S, Mahoney ME, Bullock G, Ibrado AM, Bhalla K: Combined
antileukemic activity of pIXY 321 and Ara-C against human acute myeloid leukamia cells. Leukemia &
Lymphoma 15: 445-451, 1994.
43.
Ray S, Ponnathpur V, Huang Y, Tang C, Mahoney ME, Ibrado AM, Bullock G, Bhalla K: 1--D
arabinoduranosylcytosine, mitoxantrone and paclitaxel induced apoptosis in HL-60 cells. Improved method
for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol 34: 365-371, 1994.
44.
Liu Y, Bhalla K, Hill C, Priest D: Evidence for involvement of tyrosine phosphorylation in taxol induced
apoptosis in human ovarian tumor cell line. Biochem Pharmacol 48: 1265-1272, 1994.
45.
Tang C, Willingham MC, Reed JC, Miyashita T, Tourkina E, Ponnathpur V, Huang Y, Ray S, Mahoney
ME, Bullock G, Bhalla K: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human
pre-B leukemia cells. Leukemia 8: 1960-1969, 1994.
46.
Walle T, Walle K, Kumar G, Bhalla K: Taxol metabolism and disposition in cancer patients. Drug Metab
& Dispos 23: 506-512, 1995.
47.
Bullock G, Tang C, Ray S, Reed J, Miyashita T, Ibrado AM, Huang Y, Bhalla K: Evidence against a direct
role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute
leukemia. Clin Cancer Res 1: 559-564, 1995.
Kapil N. Bhalla, M.D.
Page 9
48.
Kumar G, Ray S, Walle T, Walle K, Huang Y, Ponnathpur V, Willingham M, Self S, Ibrado AM, Bullock
G, Bhalla K: Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6hydroxytaxol. Cancer Chemother Pharmacol 36: 129-135, 1995.
49.
Bhalla K, Ibrado AM, Brandt J, Ray S, Huang Y, Tang C, Nawabi A, Hoffman R: pIXY321 protects
against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow
progenitor cells. Leukemia 9: 1851-1856, 1995.
50.
Ponnathpur V, Ibrado AM, Reed J, Ray S, Huang Y, Tang C, Bullock G, Nawabi A, Bhalla K: Effects of
modulators of protein kinase on taxol-induced apoptosis of human leukemic cells possessing disparate
levels of p26BCl-2 protein. Clin Cancer Res 1: 1399-1406, 1995.
51.
Ibrado AM, Huang Y, Fang G, Bhalla K: Bcl-xL overexpression inhibits taxol-induced Yama protease activity
and apoptosis. Cell Growth & Differ 7: 1087-1094, 1996.
52.
Bullock G, Ray S, Reed JC, Krajewski S, Self S, Ibrado AM, Huang Y, Nawabi A, Bhalla K: Intracellular
metabolism of high dose Ara-C and resulting DNA fragmentation and apoptosis of human AML cells possessing
disparate levels of p26Bcl-2 protein.
Leukemia 10: 1731-1740, 1996.
53.
Ray S, Bullock G, Nuñez G, Tang C, Ibrado AM, Huang Y, Bhalla K: Enforced expression of Bcl-xS induces
differentiation and sensitizes CML-blast crisis K562 cells to Ara-C mediated differentiation and apoptosis. Cell
Growth & Differ 7: 1617-1623, 1996.
54.
Ibrado AM, Huang Y, Fang G, Bhalla K: Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced
CPP32/Yama protease activity and apoptosis of human AML HL-60 cells. Cancer Res 56: 4743-4748, 1996.
55.
Huang Y, Ibrado AM, Nuñez G, Reed JC, Bullock G, Ray S, Tang C, Bhalla K: Co-expression of several
molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML
HL-60 cells. Leukemia 11: 253-257, 1997.
56.
Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K: Estrogen increases intracellular p26Bcl2 or p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res
& Treatment 42: 73-81, 1997.
57.
Ibrado AM, Liu L, Bhalla K: Bcl-xL overexpression inhibits progression of molecular events leading to
paclitaxel-induced apoptosis of human AML HL-60 cells. Cancer Res 57: 1109-1115, 1997.
58.
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X: Prevention of apoptosis by
Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
59.
Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ: Modulation of the
apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colonystimulating factor fusion protein. Blood 90: 3654-3661, 1997.
60.
Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G, Bhalla K: Overexpression of Bcl-xL inhibits Ara-Cinduced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of
apoptosis. Cancer Res 57: 3115-3120, 1997.
61.
Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K: Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and
activation of caspase-3. Blood 91: 1700-1705, 1998.
62.
Ilson DH, Ajani J, Bhalla K, Forastiere A, Ying H, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelson
DP: A phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the
esophagus. J Clin Oncol 16: 1826-1834, 1998.
Kapil N. Bhalla, M.D.
Page 10
63.
Bhalla K, Harris WB: Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast
cancer. Semin Oncol 25: 19-24, 1998 (Suppl 3).
64.
Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla K: ‘Loop’ domain is necessary for Taxolinduced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting Taxol-induced cytosolic
accumulation of cytochrome c (cyt c) and apoptosis. Cancer Res 58: 3202-3208, 1998.
65.
Fontana JA, Sun RJ, Rishi AK, Dawson MI, Ordonez JV, Zhang Y, Tschang SH, Bhalla K, Han Z, Wyche J,
Poirer G, Sheikh MS, Shroot B, Reichert U. Overexpression of bcl-2 or bcl-xL fails to inhibit apoptosis
mediated by a novel retinoid. Oncology Research 10 (6):313-24, 1998.
66.
Perkins C, Kim CN, Fang G, Bhalla K: Overexpression of Apaf-1 promotes apoptosis of untreated and
paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 58: 4561-4566, 1998.
67.
Ibrado AM, Kim CN, Bhalla K: Temporal relationship of CDK1 activation and mitotic arrest to cytosolic
accumulation of cytochrome c and caspase-3 activity during Taxol-induced apoptosis. Leukemia 12(12): 19301936, 1998.
68.
Balachandran S, Kim CN, Yeh W-C, Mak TW, Bhalla K, Barber GN: Activation of the dsRNA-dependent
protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 17: 6888-6902,
1998.
69.
Yu Yimin, Black JB, Goldsmith CS, Browning PJ, Bhalla K, Offermann MK: Induction of human herpesvirus8 DNA replication and transcription by butyrate and TPA in BCBL-1 cells. J Gen Virol 80:83-90, 1999.
70.
Bhalla K, Landry J, Harris WB, Daneker G, Myers M, Staley C: Phase I study of Gemcitabine, cisplatinum, 5fluorouracil and leucovorin with G-CSF support in pancreatic and other gastrointestinal cancers: a preliminary
report. Cancer Invest 17(1): 26-30, 1999.
71.
Han Z, Bhalla K, Pantazis P, Hendrickson EA, Wyche JH: Cif (Cytochrome c-efflux inducing factor) activity is
regulated by Bcl-2 and caspases and correlates with the activation of Bid. Mol Cell Biol 19(2): 1381-1389,
1999.
72.
Burri S, Kim CN, Fang G, Chang BS, Perkins C, Harris WB, Thompson CB, Bhalla K: ‘Loop’ domain
deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of
cytochrome c (cyt c), caspase-3 activity, and apoptosis. Int J Radiat Oncol Biol Phys 43(2): 423-430, 1999
73.
Kim CN, Bhalla K, Kreitman R, Willingham M, Hall P, Tagge E, Jia T, Frankel A.: Diphtheria toxin fused to
granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL60 cells. Leukemia Res 23: 527-538, 1999.
74.
Bhalla K, Kumar G, Walle, U.K., Ibrado A, Javed T, Stuart R, Reed C, Arbuck S, WalleT: Phase I and
Parmacologic study of a 3-Hour infusion of Paclitaxel followed by Cisplatinum and 5-Flourouracil in Patients
with advanced Solid Tumors. Clin Cancer Res 5: 1723-1730,1999.
75.
Balachandran S, Roberts C, Kipperman T, Bhalla K, Compans R, Archer D, Barber G: Alpha/Beta Interferons
potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. J. of
Virology 74 (3): 1513-1523, 2000.
76.
Perkins C, Kim NK, Fang G, Bhalla K: Arsenic induces apoptosis of multi-drug resistant human myeloid
leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2 or Bcl-xL. Blood 95(3): 1014-1022, 2000.
77.
Perkins C, Fang G, Kim CN, Bhalla K: The role of Apaf-1, Caspase-9, and Bid proteins in etoposide- or
paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 60(6): 1645-1653, 2000
Kapil N. Bhalla, M.D.
Page 11
78.
Fang G, Kim C, Perkins C, Ramadevi N., Winton E., Wittmann S, Bhalla K: CGP57148 (STI-571) induces
differentiation and apoptosis and sensitizes Bcr-Abl positive human leukemia cells to apoptosis due to
antileukemic drugs. Blood 96: 2246-2256 , 2000
79.
Wen J, Nguyen D, Ramadevi N, Perkins C, Orlando M, Worthington E, Jing X, Bhalla K: Anti-leukemic drugs
increase death receptor 5 levels and enhance Apo-2(TRAIL)-induced apoptosis of human acute leukemic cells.
Blood 96:3900-3906, 2000
80.
Ramadevi N, Perkins C, Orlando M, Nguyen D, O'Bryan E, Bhalla K: Pretreatment with paclitaxel enhances
Apo-2 Ligand/Tumor Necrosis Factor- related apoptosis-inducing ligand-induced apoptosis of prostate cancer
cells by inducing death receptors 4 and 5 protein levels. Cancer Research 61:766-770, 2001
81.
Ramadevi N, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K: Co-treatment with
STI-571 enhances TNF related apoptosis inducing ligand (TRAIL or Apo-2L)-induced apoptosis of Bcr-Abl
positive human acute leukemia cells. Clin. Cancer Res. 7:350-357, 2001
82.
Ramadevi N., O'Bryan E, Bhalla K. Geldanamycin and its Analogue 17-Allylamino-17Demethoxygeldanamycin (17-AAG) Lowers Bcr-Abl Level and Induces Apoptosis and Differentiation of BcrAbl Positive Human Leukemic Blasts. Cancer Res. 61:1799-1804, 2001
83.
Porosnicu M, Ramadevi N, Nguyen D, Worthington E, Perkins C, Bhalla K: Co-treatment with As2O3
Enhances Selective Cytotoxic Effects of STI571 Against Bcr-Abl Positive Acute Leukemia Cells. Leukemia
15:772-778, 2001
84.
Blagosklonny MV, Fojo T, Bhalla KN, Kim J-S, Trepel JB, Figg WD, Rivera Y, Neckers L. The Hsp90
inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Leukemia 15:1537-1543, 2001
85.
Yamaguchi H, Paranawithana S, Lee M, Huang Z, Bhalla K, Wang HG. Epothilone B analogue (BMS247550)mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer
Res. 62:466-471, 2002
86.
Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O'Bryan E, Fumero C, Bhalla K.
Ectopic Overexpression of Second Mitochondrial-Derived Activator of Caspases (Smac/DIABLO) or Cotreatment with N-terminus of Smac Peptide Potentiates Epothilone Derivative (BMS 247550) and Apo2L/TRAIL-induced Apoptosis. Blood 99:3419-3426, 2002
87.
O’Dwyer M E, La Rosee P, Nimmanapalli R, Bhalla K., Recent Advances in Philadelphia ChromosomePositive Malignancies: The Potential Role of Arsenic Trioxide. Seminars In Hematology 39:18-21, 2002
88.
Dorsey J, Cunnick J, Lanehart R, Kraker A, Bhalla K, Jove R, Wu J. Interleukin-3 protects Bcr-Abltransformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors.
Leukemia. (In Press)
89.
Huang M, Dorsey J, Epling-Burnette PK, Landowski T, Mora L, Niu G, Sinibaldi D, Nimmanapalli R, Bai F,
Kraker A, Yu H, Moscinski L, Dalton W, Bhalla K, Loughran T, Wu J, Jove R. Inhibition of Bcr-Abl kinase
activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21: 8804-16,
2002
90.
Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal
BB. Ectopic expression of protein tyrosine kinase Bcr-Abl suppresses TNF-induced NF-kappa B activation and
Ikappa Balpha phosphorylation: Relationship with downregulation of TNF receptors. J Biol Chem. 2002 Jun 11.
91.
Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl positive,
Kapil N. Bhalla, M.D.
Page 12
human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970 and 17-allylamino-17demethoxygeldanamycin (17-AAG). Cancer Res. 62:5761-5769, 2002
92.
Griffin D, Wittman D, Nimmanapalli R, Guo F, Bali F, O'Bryan E, Fiorica J, Wang H-G, Bhalla K. Molecular
Determinants of Epothilone B Derivative (BMS247550)- and Apo-2L/TRAIL- Induced Apoptosis of Human
Ovarian Cancer Cells. Gyn Oncol. (In Press)
93.
Nimmanapalli R, Bhalla K. Mechanisms of Resistance to Imatinib Mesylate (Gleevec) in Bcr-Abl Positive
Leukemias. Curr. Opin Oncl. 14:616-620, 2002
94.
Nimmanapalli R, Bhalla K. Novel targeted therapies for Bcr-Abl positive acute leukemias: Beyond STI571.
Oncogene 21:8584-8590, 2002
95.
Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Huang M, Jove R, Wang HG, Bhalla K.
Flavopiridol Downregulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone BInduced Apoptosis. (In Press)
96.
Nimmanapalli R, Stobaugh C, Fuino L, Richon VM, Bhalla K. Co-treatment with the histone deacetylase
inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive
human acute leukemia cells. (In Press)
97.
Guo F, Bhalla K. The FLIP variation on the TRAIL DISC: doxorubicin conducts the swan song. Cancer Biol.
& Ther. (In Press)
MANUSCRIPTS SUBMITTED:
1. Peterson B, Dodge R, Bhalla K, Lee E, Carpenter J, Berk G, George S, Schiffer C. High dose cytarabine with or
without concurrent GM-CSF in the treatment of relapsed or refractory acute myeloid leukemia. Submitted
2. Nimmanapalli R, Bali P, O'Bryan E, Wu J, Houghton P, Bhalla K. Arsenic trioxide inhibits translation of 5’terminal tract of oligopyrimidines (TOP) containing mRNA of bcr-abl: a mechanism that involves inhibition of
S6 kinase activity resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Submitted
3. Nimmanapalli R, O’Bryan E, Kuhn D, Bhalla K. 17-AAG-Induced downregulation of Akt, Raf-1, Erk 1/2 Src
and S6 Kinases have a reduced impact on apoptotic signaling in acute myeloid leukemia cells with
overexpression of Bcl-2 or Bcl-xL. Submitted
MANUSCRIPTS (under preparation):
1.
Guo F, Nimmanapalli R, Wittman S, Bali P, O'Bryan E, Wang HG, Bhalla K. Increased Apoptosis
Signaling in Human Acute Leukemia Cells Induced by a Combination of Ara-C and Apo-2L/TRAIL
2.
Ray S, Huang Y, Fang G, Bhalla K. Effects of retinoids, other differentiating agents and anticancer drugs
on the telomerase activity of human AML HL-60 cells.
3.
Donapaty S, Whittmann, S, Bhalla, K. Microtubule-binding drugs and apoptosis.
4.
Ray S, Fang G, Huang Y, Liu L, Bhalla K: Fenretinide: Effective inhibitor of telomerase in human breast
cancer cells.
BOOK CHAPTER
Kapil N. Bhalla, M.D.
Page 13
1.
Bhalla K, Gerson S, Grant S, Sullivan D. Pharmacology and molecular mechanism of action or resistance of
antineoplastic agents: Current status and future potential, in Hematology, Basic Principles and Practice. 2000,
Churchill Livingston: Philadelphia. p. 885-938
2.
Nimmanapalli R, Bhalla K. Targets in Apoptosis Signaling: Promise of selective anti-cancer therapy, in Tumor
Suppressor Genes: Methods and Protocols. 2002 Humana Press:
(In press)
ABSTRACTS:
1.
Grant S, Bhalla K, Egnor M, Ellison RR, Rauscher F III, Cadman E: Enhancement of Ara-C metabolism and
cytotoxicity by 2,3-dihydro-1H-imidazole-(1,2b)-pyrazole(IMPY) in human leukemic cells (HL-60) [Abstract].
Blood 58(5): 400, 1981.
2.
Grant S, Bhalla K, Scheffield K, Ellison RR, Weinstein IB, Schainholz D, Fischer PB: Differential toxicity of
bacterial cloned interferon toward leukemic versus normal bone marrow cells [Abstract]. Blood 58(5) 339,
1981.
3.
Bhalla K, Nayak R, Grant S: Potentiation of 6-thioguanine intracellular accumulation and cytotoxicity by
methotrexate in L1210 cells [Abstract]. Proc Amer Assoc Cancer Res 23: 189, 1982.
4.
Grant S, Bhalla K, Rauscher F III, Ellison RR, Cadman E: Preferential enhancement of Ara-C cytotoxicity by
2,3-dihydro-1H-imidazole-(1,2b)pyrazole (IMPY) in leukemic versus normal progenitor cells [Abstract]. Proc
Amer Assoc Cancer Res 23: 190, 1982.
5.
Bhalla K, Nayak R, Grant S: Antitumor synergism between acivicin (AT-125) and 6-thioguanine in the murine
leukemia L1210 [Abstract]. Clin Res 30(2): 414A, 1982.
6.
Bhalla K, Nayak R, Stillman I, Grant S: Isolation and characterization of Ara-C-resistant human leukemic cells
[Abstract]. Blood 60(5): 534, 1982.
7.
Bhalla K, Stillman I, Grant S: Selective eradication of Ara-C-resistant leukemic cells utilizing combinations of
thymidine and deoxycytidine [Abstract]. Blood 60(5): 535, 1982.
8.
Bhalla K, Grant S: Potentiation of high dose Ara-C activity by pyrimidine antagonists in resistant human
leukemic cells [Abstract]. Clin Res 31(2): 403A, 1983.
9.
Bhalla K, Hyman G, Grant S: Selective eradication of Ara-C-resistant leukemic cells utilizing combinations of
pyrimidine antagonists and deoxycytidine [Abstract]. Proc Amer Assoc Cancer Res 24: 1189, 1983.
10.
Bhalla K, Grant S: Ara-C metabolism in a deoxycytidine kinase-deficient, Ara-C-resistant human leukemic cell
line [Abstract]. Proc Amer Assoc Cancer Res 24: 1188, 1983.
11.
Leibowitz DS, Miller CW, Bhalla K, Grant S, Bank A: Oncogene organization and amplification in human
leukemia [Abstract]. Clin Res 1(2): 483A, 1983.
12.
Bhalla K, Grant S, Hindenburg A, Taub R: Isolation and characterization of adriamycin- resistant
leukemic cells [Abstract]. Blood 62(5): 534, 1983.
13.
Bhalla K, Grant S: Reversal of pyrimidine antagonist-mediated cytotoxicity by deoxycytidine in cultured
human leukemic and normal human myeloid progenitor cells [Abstract]. Blood 62(5): 533, 1983.
14.
Grant S, Bhalla K: Isolation and characterization of cultured human leukemic cells
resistant to 5-azacytidine [Abstract]. Blood 62(5): 714, 1983.
human
Kapil N. Bhalla, M.D.
Page 14
15.
Hindenburg A, Bhalla K, Grant S, Taub RN, Baker MA: Decreased membrance sialylation of adriamycinresistant HL-60 cells [Abstract]. Blood 62(5): 544, 1983.
16.
Bhalla K, Sweeney S, Baker M, Grant S: Deoxycytidine-mediated selective growth stimulation of normal
human myeloid progenitors (CFU-GM) [Abstract]. Blood 64(5): 412, 1984.
17.
Grant S, Bhalla K: Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic myeloid
progenitor cells [Abstract]. Proc Amer Assoc Cancer Res 26: 64, 1985.
18.
Bhalla K, Grant S: Differential effect of deoxycytidine on pyrimidine antagonist-mediated growth suppression
in normal versus leukemic human myeloid progenitor cells [Abstract]. Proc Amer Assoc Cancer Res 26: 965,
1985.
19.
Bhalla K, MacLaunghlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S: Reversal of continuouslyadministered high dose Ara-C-mediated cytotoxicity by deoxycytidine in cultured human myeloid progenitors
[Abstract]. Blood 66(5): 664, 1985.
20.
MacLaughlin W, Bhalla K, Cole J, Grant S: Differential reversal of deoxycytidine analog mediated cytotoxicity
by deoxycytidine in cultured normal and leukemic myeloid
progenitors [Abstract]. Clin Res 34(2): 566A, 1986.
21.
Grant S, Bhalla K, Graham G: Effect of thymidine and hydroxyurea on high dose Ara-C metabolism and
cytotoxicity in highly Ara-C resistant human leukemic cells [Abstract]. Proc Amer Assoc Cancer Res 28: 1288,
1987.
22.
Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S: Mechanism underlying the selective
cytotoxicity of high dose Ara-C and deoxycytidine toward humanleukemic myeloid progenitor cells [Abstract].
Proc Amer Assoc Cancer Res 28: 1287, 1987.
23.
Bhalla K, Cole J, Birkhofer M, MacLaughlin W, Grant S, Graham G: Reversal of 3'-azido-3'deoxythymidine
(AZT) and 2',3'-dideoxycytidine (DDC) mediated cytotoxicity by deoxycytidine (dCyd) in cultured normal
human myeloid progenitor cells [Abstract]. Blood 70(5): 447, 1987.
24.
Birkhofer M, Grant S, Graham G, Bhalla K: Effect of recombinant human granulocyte/macrophage colony
stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT) mediated depletion of deoxyribonucleotide
pools in normal bone marrow mononuclear cells. [Abstract]. Blood 70(5): 376, 1987.
25.
Bhalla K, MacLaughlin W, Cole J, Arlin Z, Birkhofer M, Graham G: Continuously administered 2',2'difluorodeoxycytidine (dFdC) and deoxycytidine (dCyd): A potentially selective cytotoxic regimen toward
human leukemic myeloid progenitors in culture [Abstract]. Proc Amer Assoc Cancer Res 29: 1385, 1988.
26.
Birkhofer M, Graham G, Grant S, Bhalla K: rGM-CSF and deoxycytidine protect human myeloid progenitor
cells in culture against 3'-azido-3'deoxythymidine (AZT) mediated cytotoxicity [Abstract]. Proc Am Soc Clin
Oncol 24: 5, 1988.
27.
Grant S, Bhalla K, Arlin Z, Howe C: Selective purging of human leukemic progenitors employing
combined chemothrapeutic/modified long term culture approach [Abstract]. Blood 72(5): 1468, 1988.
28.
Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky Z, Graham G: Effect of rGM-CSF and IL-3 on the metabolism
of cytosine arabinoside in normal and leukemic human bone marrow cells [Abstract]. Blood 72(5): 348, 1988.
29.
Bhalla K, Birkhofer M, Cole J, Hesdorffer, Ince C, Neugut A: Phase I study of weekly 5-fluorouracil (FU) and
leucovorin (LV) followed by hydroxyurea (HU) with allopurinol (AP) protection [Abstract]. Proc Amer Soc
Clin Oncol 8: 296, 1989.
a
Kapil N. Bhalla, M.D.
Page 15
30.
Bhalla K, Birkhofer M, Rarick M, Gill P: Modulation of the growth inhibitory effects of 2',3'-dideoxyadenosine
on human myeloid progenitor cells by rGM-CSF and Coformycin [Abstract]. Proc Amer Assoc Cancer Res 30:
2266, 1989.
31.
Grant S, Bhalla K, Arlin Z: Factors influencing deoxycytidine mediated modulation of high dose Ara-C
metabolism in human leukemic cells [Abstract]. Proc Amer Assoc Cancer Res 30: 22359, 1989.
32.
Bhalla K, Birkhofer M, Arlin Z, Grant S, Safah H, Graham G: Differential effect of Interleukin-3 on the
metabolism of cytosine arabinoside in normal versus leukemic bone marrow cells [Abstract]. Proc Amer Assoc
Cancer Res 30, 2368, 1989.
33.
Bhalla K, Kommor M, Baker M, Grant S: Deoxycytidine (IND 28108) protects against
the non-hematologic toxicity of a 96 hour continous infusion of high dose Ara-C without abrogating
antileukemic effects [Abstract]. Proc Amer Assoc Cancer Res 31: 1239, 1990.
34.
Bhalla K, Kommor M, Grant S, Lutzky J: Improved selectivity of Ara-C against AML
blasts by a combined treatment with rGM-CSF and rIL-3 [Abstract]. Proc Amer Assoc Cancer Res 31: 2505,
1990.
35.
Bullock G, Lutzky J, Holladay C, Jasiok M, Madrid K, Bhalla K: The effect of rIL-3 nd rGM-CSF on
glutathione and glutathione transferase in normal human bone marrow
cells and leukemic blasts [Abstract]. Blood 76(10): 530, 1990.
36.
Bullock G, Holladay C, Lutzky J, Jasiok M, Ibrado AM, Bhalla K: Effect of IL-6 plus IL-3 on glutathione
(GSH)/GSH S transferase in leukemic blast versus normal bone- marrow cells [Abstract]. Proc Amer Assoc
Cancer Res 32, 1884, 1991.
37.
Holladay C, Ibrado AM, Jasiok M, Bullock G, Bhalla K: Metabolism and cytotoxicity of deoxycytidine
analogues against cisplatinum resistant human ovarian cancer cells [Abstract]. Proc Amer Assoc Cancer Res 32:
2477, 1991.
38.
Bhalla K, Holladay C, Ibrado AM, Dane D, Bullock G: Effect of GM-CSF/IL-3 fusion protein (PIXY) and
mast cell growth factor (MGF) on programmed cell death induced by
high dose Ara-C (HIDAC) in human
leukemic cells [Abstract]. Blood 78(10): 64, 1991.
39.
Bullock G, Holladay C, Ibrado AM, Lutzky J, Jasiok M, Tourkina E, Mahoney ME, Dane D, Bhalla K: The
effect of IL-3 and IL-6 on 4-Hydroperoxycyclophosphamide (4-HC)- mediated programmed cell death (PCD) in
human leukemic cells [Abstract]. Blood 78(10): 63, 1991.
40.
Bhalla K, Ibrado AM, Holladay C, Bullock G: Hemopoietic growth factors (HGFs) G-CSF and IL-3 improve
the antileukemic selectivity of high dose Ara-C (HIDAC) [Abstract]. Blood 78(10): 1691, 1991.
41.
Ibrado AM, Mahoney ME, Tang C, Holladay C, Bhalla K: Effect of G-CSF on Mitoxantrone induced
programmed cell death or apoptosis in human myeloid leukemia cells [Abstract]. Proc Amer Assoc Cancer Res
33: 3043, 1992.
42.
Bhalla K, Ibrado AM, Holladay C, Bullock G, Mahoney ME, Tourkina E, Tang C: Effect of G-CSF on Ara-C
induced programmed cell death or apoptosis in human myeloid leukemia cells [Abstract]. Proc Amer Assoc
Cancer Res 33: 1573, 1992.
43.
Grant S, Bhalla K: Phase I trial of high-dose Ara-C administered as a 96 hr continuous infusion in conjunction
with a fixed dose of 2'-deoxycytidine (dCyd;IND 28108) as a host-protective agent in patients with refractory
leukemia [Abstract]. Blood 80(10): 444, 1992.
Kapil N. Bhalla, M.D.
Page 16
44.
Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Garfinkle M, Huang Y: Taxol induced programmed
cell death or apoptosis in human myeloid leukemia cells [Abstract]. Blood 80(10): 809, 1992.
45.
Bullock G, Tang C, Mahoney ME, Tourkina E, Ibrado AM, Huang Y, Bhalla K: Effect of the modulation of
protein kinase C activity on Ara-C and mitoxantrone induced programmed cell death in human myeloid
leukemia cells [Abstract]. Proc Amer Assoc Cancer Res 34: 1726, 1993.
46.
Lutzky J, Vujicic M, Yamanishi DT, Bhalla K: Antiproliferative effects of all-trans retinoic acid (9-cisRA) on
human lymphoid cell line [Abstract]. Proc Amer Assoc Cancer Res 34: 1738, 1993.
47.
Bhalla K, Huang Y, Tang C, Mahoney ME, Ibrado AM, Self S, Tourkina E, Bullock G, Willingham M:
Isolation and characterization of taxol resistant human myeloid leukemia
cells [Abstract]. Proc Amer Assoc Cancer Res 34: 1820, 1993.
48.
Ponnathpur V, Tang C, Reed JC, Huang Y, Willingham MC, Ray S, Bullock G, Bhalla K: Mechanisms of
resistance to taxol induced apoptosis in human leukemic cells [Abstract]. Blood 82(10): 1007, 1993.
49.
Bhalla K, Brandt JE, Ray S, Bruno E, Ibrado AM, Tang C, Ponnathpur V, Huang Y, Hoffman R: Effect of a
combination of IL-3 and GM-CSF on Ara-C or taxol induced apoptosis in normal human marrow progenitor
cells [Abstract]. Blood 82(10): 1008, 1993.
50.
Bleiler JK, Tang C, Lutzky J, Mahoney ME, Huang Y, Bhalla K: Taxol induced apoptosis in human myeloma
cells [Abstract]. Blood 82(10): 2221, 1993.
51.
Ponnathpur V, Tang C, Ibrado AM, Ray S, Mahoney ME, Huang Y, Bullock G, Bhalla K: Increased apoptotic
cell death of human myeloid leukemia cells treated with taxol followed by Ara-C [Abstract]. Proc Amer Assoc
Cancer Res 35: 1867, 1994.
52.
Ibrado AM, Ponnathpur V, Reed J, Tang C, Huang Y, Ray S, Bullock G, Mahoney ME, Bhalla K: Protein
kinase C and tryosine kinase activities affect taxol induced apoptosis in human leukemic cells [Abstract]. Proc
Amer Assoc Cancer Res 35: 1868, 1994.
53.
Walle T, Bhalla K, Walle UK, Kumar GN, Stuart RK: Taxol disposition in humans after tritium-labeled drug
[Abstract]. Proc Amer Soc Clin Oncol 13: 404, 1994.
54.
Bhalla K, Kumar GN, Walle T, Stuart RK: Phase I and pharmacokinetic trial of a 3 hour infusion of taxol (T),
cisplatin (CP) plus 5-Fluorouracil (5-FU) in advanced solid tumors [Abstract]. Proc Amer Soc Clin Oncol 13:
454, 1994.
55.
Bullock G, Ray S, Nawabi A, Huang Y, Ibrado AM, Bhalla K: Mechanisms and partial
reversal of resistance to antileukemic drug-induced apoptosis in CML blast crisis K562 cells [Abstract]. Blood
84(10): 610, 1994.
56.
Ibrado AM, Ray S, Ponnathpur V, Huang Y, Nawabi A, Bullock G, Bhalla K: Regulation of taxol-induced
apoptosis in human AML cells [Abstract]. Blood 84(10): 2464, 1994.
57.
Kumar GN, Bhalla K, Walle UK, Walle T: Dose-dependent pharmacokinetics of paclitaxel (Taxol) in adult
cancer patients after a 3-hour infusion [Abstract]. Proc Pharm Res 11: 8391, 1994.
58.
Bullock G, Nawabi A, Ray S, Ibrado AM, Tang C, Huang Y, Bhalla K: High intracellular p26BCL-2 levels
block high dose Ara-C induced DNA fragmentation and apoptosis in human myeloid leukemia cells [Abstract].
Proc Amer Assoc Cancer Res 36: 2472, 1995.
59.
Bhalla K, Huang Y, Ray S, Tang C, Ibrado AM, Holycross M, Nawabi A: Taxol-induced apoptosis in estrogen
responsive and unresponsive human breast cancer cells [Abstract]. Proc Amer Assoc Cancer Res 36: 2473,
Kapil N. Bhalla, M.D.
Page 17
1995.
60.
Ajani JA, Ilson D, Bhalla K, Forastiere A, Pazdur R, Martin L, Daugherty K, and Kelsen DP: Taxol, cisplatin,
and 5-FU (TCF): A multi-institutional phase II study in patients with carcinoma of the esophagus [Abstract].
Proc Amer Soc Clin Oncol 14: 489, 1995.
61.
Javed T, Reed C, Walle T, Stuart RK, Ibrado AM, Bhalla K: A regimen of paclitaxel (P), cisplatin (CP) and 5Fluorouracil (FU) followed by G-CSF is highly active against epidermoid and adenocarcinoma of esophagus
[Abstract]. Proc Amer Soc Clin Oncol 14: 456, 1995.
62.
Ibrado AM, Ray S, Nuñez G, Bullock G, Tang C, Huang Y, Bhalla K: Enforced over-expression of the Bcl-xS
gene induces differentiation and sensitizes CML blast crisis K562 cells to Ara-C-mediated differentiation and
apoptosis [Abstract]. Blood 86(10):1298, 1995.
63.
Bullock G, Ray S, Reed JC, Stanislaw K, Ibrado AM, Huang Y, Bhalla K: Intracellular metabolism of high dose
Ara-C and resulting DNA fragmentation and apoptosis of human AML cells possessing widely disparate levels
of p26Bcl-2 and p29Bcl-xL proteins [Abstract]. Blood 86(10): 2047, 1995.
64.
Ibrado AM, Ray S, Nuñez G, Huang Y, Bullock G, Fang G, Bhalla K: Effect of Bcl-xL overexpression on
CPP32/Yama nRNA induction and protease activity during Ara-C and taxol-induced apoptosis in human AML
cells [Abstract]. Proc Amer Assoc Cancer Res 37: 414, 1996.
65.
Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K: Bcl-xL overexpression inhibits Ara-C-induced alterations in
free to heterodimerized Bax, CPP32/Yama protease activity and apoptosis of human AML HL-60 cells
[Abstract]. Blood 88(10): 2636, 1996.
66.
Ray S, Huang Y, Fang G, Liu L, Bhalla K: Effects of retinoids, other differentiating agents and anticancer drugs
on the telomerase activity of human AML HL-60 cells [Abstract]. Blood 88(10): 307, 1996.
67.
Huang Y, Kim N, Fang G, Liu L, Bhalla K: Molecular correlates of enhancement of paclitaxel-induced
apoptosis by co-treatment with 7-hydroxystaurosporine (UCN-01) [Abstract]. Proc Amer Assoc Cancer Res 38:
3567, 1997.
68.
Harris WB, Huang Y, Fang G, Ray S, Liu L, Bhalla K: Molecular regulation of paclitaxel-induced apoptosis of
human esophageal and breast cancer cells: role of Bcl-2 and Bcl-xL [Abstract]. Proc Amer Soc Clin Oncol 16:
1969, 1997.
69.
Singh S, Bhalla K, Swerlick RA: Effects of serum and vascular endothelial growth factor (VEGF) on the
molecular determinants of apoptosis of human dermal microvascular endothelial cells (HDMEC) [Abstract].
Proc Amer Assoc Cancer Res 39: 986, 1998.
70.
Harris WB, Bhalla K: Apoptosis induced by topotecan and 9-aminocamptothecin is mediated by the release of
cytochrome c from mitochondria in HL-60 leukemia cells [Abstract]. Proc Amer Assoc Cancer Res 39: 483,
1998.
71.
Burri S, Liu L, Perkins C, Davis L, Bhalla K: Effect of Bcl-xL or its ‘loop’ domain deletional mutant expression
on irradiation-induced cytosolic cytochrome c (cyt c), caspase-3 activity and apoptosis [Abstract]. Proc Amer
Assoc Cancer Res 39: 530, 1998.
72.
Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla K: Deletional mutant of ‘loop’ domain of Bcl-2
inhibits Ara-C and etoposide but not taxol-induced cytosolic accumulation of cytochrome c (cyt c) and apoptosis
[Abstract]. Proc Amer Assoc Cancer Res 39: 1214, 1998.
73.
Perkins C, Kim CN, Fang G, Jia T, Whittman S, Bhalla K: Role of Apaf-1 in the regulation of the molecular
cascade of anticancer drug-induced apoptosis. [Abstract]. Proc Amer Assoc Cancer Res 40: 737, 1999.
Kapil N. Bhalla, M.D.
Page 18
74.
Fang G, He J, Whittman S, Jia T, Kim CN, Yalowich JC, Bhalla K : Molecular determinants of the
antiapoptotic and antidifferentiating effects of Bcr-Abl kinase in human leukemic cells. [Abstract]. Proc Amer
Assoc Cancer Res 40: 737, 1999.
75.
Wen J, Nguyen D, Fang G, Perkins C, Orlando M, Jing X, Bhalla K: Novel anti-leukemic strategy combining
TRAIL (Apo-2 ligand) and antileukemic cytotoxicity drugs, Ara-C, etoposide or doxorubicin. [Abstract]. Blood
94: 278a, 1999
76.
Perkins C, Fang G, Orlando M, Porosnicu M, Kim C, Whittman S, Wen J, Bhalla K: Novel anti-Bcr-Abl
strategy consisting of Arsenic Trioxide and CGP57148B lowers Bcr-Abl levels and tyrosine kinase activity
resulting in apoptosis and differentiation of Bcr-Abl positive human leukemia cells. [Abstract]. Blood 94:592a,
1999.
77.
N. Ramadevi, J. Wen, C. Perkins, M. Orlando, D. Nguyen, K. Bhalla. University of Miami, Sylvester
Comprehensive Cancer Center, Miami, FL 33136. Molecular Determinants Of Additive Apoptotic Effects Of
Chemotherapeutic Agents And Trail (Apo2L). [Abstract]. Proc Amer Assoc Cancer Res 41: 448, 2000
78.
C. Perkins, N. Ramadevi, M. Porosnicu , G. Fang, M. Orlando, D. Nguyen, K. Bhalla. Novel Anti-Bcr-Abl
Strategies Incorporating STI571 (CGP57148b), Arsenic Trioxide (AT) And Trail (Apo2L) Against Bcr-Abl
Positive Human Leukemic Cells. University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
33136 [Abstract]. Proc Amer Assoc Cancer Res 41: 2472, 2000
79.
Griffin D, Nimmanapalli R, Wittman S, Guo F, O’Bryan E, Bhalla K. Molecular determinants of Apo2L/TRAIL and paclitaxel-induced apoptosis in human ovarian and prostate cancer cells. [Abstract] Proc Amer
Assoc Cancer Res 42: 3451, 2001
80.
Nimmanapalli R, O’Bryan E, Bhalla K. 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) lowers Bcr-Abl
levels and induces differentiation and apoptosis of STI-571 sensitive and resistant Bcr-Abl positive acute
leukemia cells. [Abstract] Proc Amer Assoc Cancer Res 42: 4293, 2001
81.
Nimmanapalli R, Bali P, O’Bryan E, Kuhn D, Bhalla K. Mechanism by which arsenic trioxide downregulates
Bcr-Abl levels and potentiates Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells
[abstract]. Blood 98:2589, 2001
82.
Guo F, Nimmanapalli R, Paranawithana S, Bali P, O’Bryan E, Bhalla K. Mechanism of potentiation of Ara-C
induced apoptosis of human acute leukemia cells by Apo-2L/TRAIL and Smac peptide [Abstract]. Blood
98:3343, 2001
83.
D Griffin, F Guo, R Nimmanapalli, S Paranwithana, S Wittman, E O'Bryan, P Bali, K N Bhalla. Mechanism of
potentiation of epothilone-induced apoptosis of human ovarian cancer and leukemia cells by Apo-2L/TRAIL and
Smac peptide. [Abstract] AACR-EORTC-NCI, 2001
84.
Wittman S, Paranwithana S, Nimmanapalli R, Bali P, O'Bryan E, Guo F, Wang HG, Bhalla K. Survivin and
mitotic kinase as targets for enhancing Epothilone B-induced mitotic arrest and apoptosis of Human breast
cancer cells. [Abstract] Proc Amer Assoc Cancer Res. 43:2031, 2002
85.
Nimmanapalli R, Kuhn D, O'Bryan E, Bali P, Kapil N Bhalla. 17-AAG-induced apoptotic signaling in acute
myeloid leukemia cells through downregulation of Akt, Raf, Erk and Src kinases and its inhibition by Bcl-2 and
Bcl-xL [Abstract] Proc Amer Assoc Cancer Res. 43:1642, 2002
86.
Donapaty S, Diaz, N., Yamaguchi H, Wittman S, Nimmanapalli R, Guo F, Bali P, Wang HG, Bhalla K.
Role of Proapoptotic Bim in the Anti-breast Cancer Activity of Taxotere or Epothilone B.[Abstract] Breast
Cancer Symposium, 2002
Kapil N. Bhalla, M.D.
Page 19
87.
Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Huang M, Jove R, Wang HG, Bhalla K.
Flavopiridol Downregulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone
B-Induced Apoptosis. [Abstract] Breast Cancer Symposium, 2002
88.
Guo, F., Wittmann, S. Richon, V., Bhalla, K. Co-treatment with the histone deacetylase inhibitor
suberoylanilide hydroxamic acid (SAHA) enhances Apo-2L/TRAIL-induced death inducing signaling
complex and apoptosis of human acute lymphoid leukemia cells. [Abstract] ASH, 2002.
89.
Nimmanapalli, R., Bali, P., O'Bryan, E., Wu, J., Houghton, P., Bhalla, K. Arsenic trioxide inhibits
translation of 5’-terminal tract of oligopyrimidines (TOP) containing mRNA of bcr-abl: a mechanism that
involves inhibition of S6 kinase activity resulting in attenuation of Bcr-Abl levels and apoptosis of human
leukemia cells. [Abstract] ASH, 2002.
90.
Nimmanapalli, R., Stobaugh, C., Fuino, L., Richon, V., Bhalla, K. Co-treatment with the histone
deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances the cytotoxic effects of Gleevec
and arsenic trioxide (AT) against Bcr-Abl positive human leukemia cells. [Abstract] ASH, 2002.